OA
GMAB icon

Operose Advisors’s Genmab GMAB Stock Holding History

Operose Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-385
Closed -$9.39K – 521
2024
Q3 		$9.39K Hold
385
– – ﹤0.01% 501
2024
Q2 		$9.68K Hold
385
– – ﹤0.01% 453
2024
Q1 		$11.5K Hold
385
– – ﹤0.01% 469
2023
Q4 		$12.3K Hold
385
– – ﹤0.01% 435
2023
Q3 		$13.6K Buy
+385
New +$14.7K 0.01% 538

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Operose Advisors's GMAB Position: Q4 2024 in Review

Operose Advisors sold out of Genmab (GMAB) in Q4 2024, closing a stake of 385 shares — an estimated $9.39K sold.

Operose Advisors first reported a position in GMAB in Q3 2023 and held it in 5 quarters. The position peaked at $13.6K in Q3 2023. 228 funds tracked by Wall St. Rank hold GMAB as of Q4 2024.

  • Operose Advisors reported no remaining Genmab position as of Q4 2024 after selling out during the quarter.
  • Operose Advisors sold 385 Genmab shares in Q4 2024, an estimated $9.39K.
  • Operose Advisors first reported a position in Genmab in Q3 2023 and held it in 5 quarters.
  • Operose Advisors's Genmab position peaked at $13.6K in Q3 2023.
  • 228 funds tracked by Wall St. Rank held Genmab as of Q4 2024.

Based on Operose Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.